Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BKM120 in PIK3CA-mutated solid tumors
NCT01501604Phase 2Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2012
- Primary completion
- Aug 2013
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of buparlisib in lung cancer, breast cancer, colorectal cancer (CRC), cholangiocarcinoma (CCA), solid tumor, sponsored by Massachusetts General Hospital. Planned start Jan 2012; status: withdrawn.
02
Drugs
buparlisib
03
Conditions
lung cancerbreast cancercolorectal cancer (CRC)cholangiocarcinoma (CCA)solid tumor
Beyond the preview
Go deeper on NCT01501604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01501604.